Get the Stockscreener App
16.23
8.31%
-1.47
After Hours:
16.40
0.17
+1.05%
Arvinas Inc stock is traded at $16.23, with a volume of 1.03M.
It is down -8.31% in the last 24 hours and down -5.09% over the past month.
Arvinas Inc is a United States-based biopharmaceutical company focused on improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development and commercialization of therapies that degrade disease-causing proteins.. The company's proprietary Proteolysis-Targeting Chimera (PROTAC), work by inducing the cell's own ubiquitin-proteasome system to target, degrade and remove disease-causing proteins. The group's product candidates are bavdegalutamide, ARV-471 and ARV-766.
See More
Previous Close:
$17.70
Open:
$17.77
24h Volume:
1.03M
Relative Volume:
1.06
Market Cap:
$1.12B
Revenue:
$161.10M
Net Income/Loss:
$-308.60M
P/E Ratio:
-3.4754
EPS:
-4.67
Net Cash Flow:
$-259.90M
1W Performance:
-3.10%
1M Performance:
-5.09%
6M Performance:
-36.35%
1Y Performance:
-65.69%
1-Day Range:
$16.21
$18.00
1-Week Range:
$16.21
$18.18
52-Week Range:
$16.07
$49.76
Arvinas Inc Stock (ARVN) Company Profile
Name
Arvinas Inc
Sector
Industry
Phone
203-535-1456
Address
395 WINCHESTER AVE, NEW HAVEN, CT
Compare ARVN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ARVN
Arvinas Inc
|
16.23 | 1.12B | 161.10M | -308.60M | -259.90M | -4.67 |
|
VRTX
Vertex Pharmaceuticals Inc
|
483.31 | 124.11B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
684.87 | 74.87B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
622.61 | 37.83B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
243.53 | 31.53B | 2.25B | -278.16M | -42.59M | -2.17 |
|
BNTX
Biontech Se Adr
|
111.56 | 26.75B | 3.30B | -501.07M | 1.03B | -2.1146 |
Arvinas Inc Stock (ARVN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-10-24 | Initiated | BTIG Research | Buy |
| Nov-18-24 | Initiated | Stephens | Overweight |
| Feb-28-24 | Reiterated | Oppenheimer | Outperform |
| Feb-14-24 | Downgrade | Citigroup | Buy → Neutral |
| Feb-01-24 | Initiated | Goldman | Buy |
| Dec-19-23 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Dec-06-23 | Upgrade | Jefferies | Hold → Buy |
| Nov-20-23 | Upgrade | Guggenheim | Neutral → Buy |
| Oct-23-23 | Upgrade | Wedbush | Neutral → Outperform |
| Jun-26-23 | Resumed | Oppenheimer | Outperform |
| Jan-12-23 | Downgrade | Guggenheim | Buy → Neutral |
| Jan-03-23 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Sep-09-22 | Initiated | Barclays | Overweight |
| Jun-21-22 | Initiated | Jefferies | Hold |
| May-09-22 | Downgrade | Wedbush | Outperform → Neutral |
| Apr-28-22 | Initiated | Credit Suisse | Outperform |
| Apr-06-22 | Initiated | Morgan Stanley | Equal-Weight |
| Feb-11-22 | Resumed | BMO Capital Markets | Outperform |
| Feb-10-22 | Initiated | Wells Fargo | Overweight |
| Jan-19-22 | Initiated | Goldman | Buy |
| Dec-07-21 | Initiated | Cowen | Outperform |
| Oct-14-21 | Initiated | SVB Leerink | Outperform |
| Sep-30-21 | Initiated | Stifel | Buy |
| Sep-09-21 | Initiated | BofA Securities | Buy |
| May-21-21 | Initiated | UBS | Buy |
| Apr-21-21 | Initiated | Truist | Buy |
| Mar-31-21 | Initiated | BMO Capital Markets | Outperform |
| Dec-14-20 | Upgrade | Oppenheimer | Perform → Outperform |
| Jun-01-20 | Upgrade | Citigroup | Neutral → Buy |
| May-12-20 | Initiated | Oppenheimer | Perform |
| Dec-19-19 | Initiated | H.C. Wainwright | Buy |
| Nov-25-19 | Initiated | Guggenheim | Buy |
| Oct-24-19 | Upgrade | Goldman | Neutral → Buy |
| Sep-25-19 | Initiated | Wedbush | Outperform |
| Sep-12-19 | Initiated | BMO Capital Markets | Outperform |
| Aug-06-19 | Initiated | Cantor Fitzgerald | Overweight |
| Jun-05-19 | Downgrade | Citigroup | Buy → Neutral |
| Apr-12-19 | Initiated | Evercore ISI | Outperform |
| Oct-22-18 | Initiated | Citigroup | Buy |
| Oct-22-18 | Initiated | Goldman | Neutral |
| Oct-22-18 | Initiated | Piper Jaffray | Overweight |
View All
Arvinas Inc Stock (ARVN) Latest News
Wall Street Analysts Predict a 228.87% Upside in Arvinas (ARVN): Here's What You Should Know - Yahoo Finance
Arvinas, Inc. (NASDAQ:ARVN) Insider Sells $150,724.20 in Stock - MarketBeat
Arvinas, Inc. (NASDAQ:ARVN) CEO Sells $523,971.36 in Stock - MarketBeat
David K. Loomis Sells 1,214 Shares of Arvinas, Inc. (NASDAQ:ARVN) Stock - MarketBeat
Arvinas (NASDAQ:ARVN) Hits New 52-Week LowShould You Sell? - MarketBeat
Have Arvinas Insiders Been Selling Stock? - Simply Wall St
Arvinas’s SWOT analysis: biotech firm’s stock hinges on cancer drug trials - Investing.com
Arvinas chief scientific officer sells $70,238 in stock By Investing.com - Investing.com South Africa
Long Term Trading Analysis for (ARVN) - Stock Traders Daily
Arvinas president of R&D sells $150,752 in stock By Investing.com - Investing.com South Africa
Arvinas chief scientific officer sells $70,238 in stock - Investing.com
Arvinas Insider Sold Shares Worth $523,881, According to a Recent SEC Filing -February 25, 2025 at 06:49 am EST - Marketscreener.com
Arvinas president of R&D sells $150,752 in stock - Investing.com
Arvinas Executives Sell Shares to Cover Tax Obligations - TradingView
Arvinas (ARVN) Expected to Announce Quarterly Earnings on Tuesday - MarketBeat
Arvinas stock hits 52-week low at $16.55 amid market challenges - Investing.com Australia
Arvinas stock hits 52-week low at $16.55 amid market challenges By Investing.com - Investing.com South Africa
Arvinas (NASDAQ:ARVN) Trading 7.4% HigherHere's What Happened - MarketBeat
Arvinas (NASDAQ:ARVN) shareholders have endured a 72% loss from investing in the stock three years ago - Yahoo Finance
Arvinas (ARVN) to Release Quarterly Earnings on Tuesday - MarketBeat
Arvinas, Inc. (NASDAQ:ARVN) Sees Significant Growth in Short Interest - MarketBeat
All You Need to Know About Arvinas (ARVN) Rating Upgrade to Buy - MSN
Arvinas Operations describes new DGK-α inhibitors - BioWorld Online
What is HC Wainwright's Estimate for Arvinas Q3 Earnings? - MarketBeat
Wedbush Estimates Arvinas' Q1 Earnings (NASDAQ:ARVN) - MarketBeat
Earnings call transcript: Arvinas Q4 2024 surpasses EPS forecast, stock rises - Investing.com Nigeria
Q1 Earnings Forecast for Arvinas Issued By Leerink Partnrs - MarketBeat
Arvinas, Inc. (NASDAQ:ARVN) Given Average Recommendation of "Buy" by Analysts - MarketBeat
Oppenheimer Forecasts Strong Price Appreciation for Arvinas (NASDAQ:ARVN) Stock - MarketBeat
Arvinas (NASDAQ:ARVN) Receives Buy Rating from Guggenheim - MarketBeat
Analysts Offer Predictions for Arvinas FY2029 Earnings - MarketBeat
Arvinas (NASDAQ:ARVN) Stock Price Up 5% Following Better-Than-Expected Earnings - MarketBeat
Arvinas (NASDAQ:ARVN) Given "Outperform" Rating at BMO Capital Markets - MarketBeat
Stifel Nicolaus Has Lowered Expectations for Arvinas (NASDAQ:ARVN) Stock Price - MarketBeat
Wedbush Reiterates Outperform Rating for Arvinas (NASDAQ:ARVN) - MarketBeat
How the (ARVN) price action is used to our Advantage - Stock Traders Daily
Arvinas anticipates Phase 3 topline results for vepdegestrant in Q1 2025 with commercial preparations underway - MSN
Arvinas (NASDAQ:ARVN) Posts Quarterly Earnings Results, Beats Estimates By $0.44 EPS - MarketBeat
Arvinas Inc Stock (ARVN) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.13%
1.23%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):